Researchers at the MIT Media Lab have developed a groundbreaking technology called HITMAN, which uses injectable nanoantennas to create targeted electric fields that could treat drug-resistant glioblastoma, one of the most aggressive and difficult-to-treat brain cancers. These nanoantennas are about 150 nanometers in size—roughly 1/1000th the width of a human hair—and can be activated wirelessly using a low-frequency magnetic field. This magnetic field can pass through the skull and brain tissue to trigger the nanoantennas, which then generate localized electric fields that specifically target and destroy cancer cells without harming healthy tissue. In laboratory tests using human cancer cells obtained from the Mayo Clinic, HITMAN eliminated nearly half of the drug-resistant cancer cells, outperforming the standard chemotherapy drug temozolomide (TMZ). When tested in mice with implanted human tumor cells, the nanoantennas significantly slowed tumor growth and extended survival by more than 50%. Importantly, no major toxic effects were observed in the animals' organs or surrounding healthy brain tissue. The effectiveness of HITMAN stems from the unique properties of cancer cells, which grow rapidly and have abnormal cell membranes and organelles. These characteristics make them more vulnerable to the electric fields generated by the nanoantennas. The electric fields cause structural damage to the cells, including protein unfolding, membrane disruption, and stress within the endoplasmic reticulum, ultimately leading to cell death. Control experiments confirmed that the nanoantennas were responsible for these effects, with no harmful impact on other parts of the body. If successfully translated into clinical use, the nanoantennas could be injected directly into the brain or delivered through the bloodstream using a related technology called "circulatronics." This approach allows electronic devices to travel through the body and reach the brain without triggering an immune response or being blocked by the blood-brain barrier, as shown in earlier studies. Glioblastoma is notoriously difficult to treat due to its ability to spread through brain tissue, its resistance to conventional therapies, and its ability to suppress the immune system. The researchers emphasize the need for new, targeted treatment strategies, and HITMAN offers a promising, minimally invasive option that could be adapted for clinical use. The findings were published in the journal Science Advances.